189 related articles for article (PubMed ID: 33005653)
1. Paraneoplastic Thromboembolism and Thrombophilia: Significance in Visceral Medicine.
Pfrepper C
Visc Med; 2020 Aug; 36(4):280-287. PubMed ID: 33005653
[TBL] [Abstract][Full Text] [Related]
2. Venous and Arterial Thromboembolism in Patients With Cancer:
Gervaso L; Dave H; Khorana AA
JACC CardioOncol; 2021 Jun; 3(2):173-190. PubMed ID: 34396323
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
4. OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism.
Ross JA; Miller M; Hernandez CR
Thromb Res; 2016 Apr; 140 Suppl 1():S173-4. PubMed ID: 27161685
[TBL] [Abstract][Full Text] [Related]
5. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
6. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants in patients with liver cirrhosis: A systematic review.
Hoolwerf EW; Kraaijpoel N; Büller HR; van Es N
Thromb Res; 2018 Oct; 170():102-108. PubMed ID: 30153564
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
9. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism.
Recio-Boiles A; Veeravelli S; Vondrak J; Babiker HM; Scott AJ; Shroff RT; Patel H; Elquza E; McBride A
World J Gastrointest Oncol; 2019 Oct; 11(10):866-876. PubMed ID: 31662825
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study.
Blin P; Samama CM; Sautet A; Benichou J; Lignot-Maleyran S; Lamarque S; Lorrain S; Lassalle R; Droz-Perroteau C; Mismetti P; Moore N
Pharmacol Res; 2019 Mar; 141():201-207. PubMed ID: 30583081
[TBL] [Abstract][Full Text] [Related]
14. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study.
Gerotziafas GT; Taher A; Abdel-Razeq H; AboElnazar E; Spyropoulos AC; El Shemmari S; Larsen AK; Elalamy I;
Oncologist; 2017 Oct; 22(10):1222-1231. PubMed ID: 28550032
[TBL] [Abstract][Full Text] [Related]
15. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism.
Hannevik TL; Brekke J; Enden T; Frøen H; Garresori H; Jacobsen EM; Paulsen PQ; Porojnicu AC; Ree AH; Torfoss D; Velle EO; Wik HS; Ghanima W; Sandset PM; Dahm AEA
Thromb Res; 2020 Dec; 196():238-244. PubMed ID: 32919178
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis.
Serrao A; Merli M; Lucani B; Aprile F; Fiori L; Gioia S; Breccia M; Riggio O; Chistolini A
Eur J Clin Invest; 2021 Jan; 51(1):e13356. PubMed ID: 33180323
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism in benign esophageal surgery patients: potential cost effectiveness of Caprini risk stratification.
Perez SA; Reddy SB; Meister A; Pinjic E; Suzuki K; Litle VR
Surg Endosc; 2022 Jan; 36(1):764-770. PubMed ID: 33492505
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism (VTE) risk stratification in general medical patients at an academic medical center.
Fritz MK; Kincaid SE; Sargent CG; Green AH; Davis GA
J Thromb Thrombolysis; 2021 Jan; 51(1):67-73. PubMed ID: 32447745
[TBL] [Abstract][Full Text] [Related]
20. Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.
Nutescu EA
Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S5-13. PubMed ID: 17519445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
